COMPANY INFO
Pendulum, founded in 2012 and headquartered in San Francisco, is a biotechnology company specializing in microbiome interventions and drugs designed to improve healthcare by managing chronic illnesses and type 2 diabetes. The company was co-founded by Colleen Cutcliffe (CEO), John Eid (CSO), and Jim Bullard, all scientists with extensive backgrounds in microbiology and biochemistry. Pendulum has approximately 143 employees as of 2025 and operates primarily in the Other Consumer Non-Durables industry. Their mission is to create microbiome products that combine the power and efficacy of pharmaceuticals with the safety and accessibility of probiotics. The official website is https://pendulumlife.com.
Pendulum Therapeutics, Inc. is a San Francisco-based biotechnology company founded in 2012, focused on developing microbiome-based therapies and interventions to address chronic illnesses such as type 2 diabetes. By merging pharmaceutical rigor with the accessibility of probiotics, Pendulum aims to fundamentally improve healthcare outcomes through advanced microbiome science.
The Pendulum Therapeutics, Inc. executive team boasts deep expertise across microbiology, biostatistics, biotechnology, clinical medicine, finance, supply chain, and brand marketing. Pendulum's founders and leadership bring decades of combined experience in their respective fields, ensuring robust scientific research, innovation, scalable operations, and effective market engagement for the company's growing portfolio of therapeutic products.
As CEO and co-founder, Colleen Cutcliffe leads Pendulum Therapeutics, Inc.'s strategic vision and execution, overseeing product development, clinical trials, and commercialization of microbiome-based therapeutics. Colleen has notably spearheaded the launch of Pendulum Glucose Control, a capsule designed to improve metabolic health for individuals living with type 2 diabetes, and has been instrumental to the company’s rapid growth and market recognition.
Cutcliffe holds a Ph.D. in Biochemistry and Molecular Biology from Johns Hopkins University and a B.A. in Biochemistry from Wellesley College. Her career includes postdoctoral research at Northwestern's Children's Memorial Hospital, senior management at Pacific Biosciences, and roles at Elan Pharmaceuticals, supplying over 15 years of leadership experience in academia, biotechnology, and pharmaceuticals.
As Chief Science Officer and co-founder, John Eid leads Pendulum Therapeutics, Inc.'s R&D, overseeing the application of next-generation DNA sequencing and systems biology to the microbiome, which enables new probiotic and metabolic mapping technologies. John has been central to the development of Pendulum's proprietary, evidence-based formulations that differentiate the company's offerings.
Eid earned a Ph.D. in Biophysics and Computational Biology at the University of Illinois, Urbana-Champaign and a B.S. in Applied and Engineering Physics from Cornell University. His track record includes serving as Principal Scientist at Pacific Biosciences and completing postdoctoral research at Harvard's Roland Institute, with two decades of experience in advanced microscopy, genome sequencing, and single-molecule detection.
Jim Bullard, as co-founder, helped establish Pendulum’s foundational scientific platform, specializing in experimental design, statistical modeling, and bioinformatics for converting microbiome research into clinical probiotic products. His statistical acumen has underpinned clinical and preclinical studies, advancing product development.
Bullard holds a Ph.D. in Biostatistics from UC Berkeley and a B.A. in Computing & Information Systems from Northwestern University. He previously served as Senior Staff Scientist at Pacific Biosciences, providing critical expertise in computational biology and experimental methodologies.
Dr. Adam Perlman oversees clinical development, medical affairs, and engagement with physicians, integrating Pendulum’s microbiome therapeutics into clinical practice. He drives clinical evidence generation to substantiate the safety and efficacy of Pendulum’s metabolic health solutions.
Dr. Perlman is board-certified in Internal Medicine, holds an MD and MPH from Boston University, and formerly directed Integrative Health at Mayo Clinic and held executive leadership at Duke University Health System. His 25+ years’ experience unites clinical leadership, wellness innovation, and healthcare strategy.
As CFO, Andrey Reznik manages financial planning, capital allocation, and investor relations, ensuring Pendulum’s sustained growth and resource optimization. Reznik has played a key role in executing funding rounds and building the fiscal discipline to scale R&D and commercial operations.
Reznik previously served as Vice President of Strategic Finance and VP of Business Development at Pendulum. His earlier finance experience includes roles at Inverness Advisors and Burrill & Company, and he is a Cornell University alumnus with extensive expertise in biotech finance and investment strategy.
Suzanne McDonnell steers Pendulum’s brand strategy, marketing communications, and customer engagement, fueling the company’s market presence and consumer adoption of microbiome-based therapeutics. She has orchestrated brand launches and initiatives that drive market awareness and build lasting consumer trust.
McDonnell previously held executive marketing roles including ELT Chief Commercial Officer at BARK and Board Member at Fi. She is a graduate of Colgate University and brings over a decade of experience in brand strategy and lifecycle marketing for consumer health and biotech products.
Brian Stout leads global supply chain, manufacturing, and quality operations for Pendulum, scaling production of probiotic therapeutics and ensuring compliance with health regulations. His leadership has optimized logistics and supported the company’s commercial distribution efforts.
Stout holds an MBA from Georgia Tech Scheller College of Business and has previously served as Chief Supply Chain Officer at Thistle. He has held senior operations roles in biopharma and brings extensive knowledge of supply chain innovation and large-scale manufacturing logistics.
Jared Toboni drives operations strategy and process optimization, aligning supply chain and sourcing efforts with Pendulum's corporate growth objectives. His initiatives improve operational efficiency and underpin Pendulum's ability to scale therapeutics delivery.
Toboni holds a Master’s Degree from Cal Poly San Luis Obispo and previously served in supply chain leadership at Visby Medical. His experience spans sourcing, supply chain engineering, and global procurement.
David Raksin directs financial strategy, budgeting, and strategic partnerships, supporting Pendulum’s business development and M&A activities. He plays a crucial role in expanding the product pipeline and reach of Pendulum’s groundbreaking therapeutics.
Raksin served as VP of Business Development at Pendulum and previously held director-level finance roles at Inverness Advisors and Burrill & Company. He is a Cornell University graduate with a robust background in corporate finance and deal structuring.
Becky Markus McIntosh oversees brand and product marketing, orchestrating go-to-market strategies, digital campaigns, and customer segmentation to support product launches and drive market penetration for Pendulum’s therapeutics.
She earned an MBA from Harvard Business School, and previously led global brand marketing at 23andMe and was Marketing Director at Discovery Channel, with early experience at Procter & Gamble. Her consumer brand management background accelerates Pendulum’s growth and brand differentiation.
Pendulum Therapeutics, Inc.'s leadership team blends scientific rigor, operational expertise, and strategic marketing to steer the company through rapid expansion and clinical innovation. The team is structured to capitalize on scientific discovery, efficient production, disciplined finance, and powerful storytelling—reflecting Pendulum’s commitment to transforming chronic disease care with microbiome-driven solutions. With a mix of pioneering founders and experienced executives, the company maintains a lean yet impactful management structure.
Websets is a powerful natural language search and data enrichment tool that helps you research executive teams for any company. Whether you're analyzing the Pendulum Therapeutics, Inc. leadership team or exploring management structures at other organizations, Websets provides comprehensive insights into executive backgrounds, roles, and team dynamics.
With Websets, you can access detailed executive team profiles, management structures, and leadership insights through intuitive natural language queries. Sign up now to enhance your executive team research capabilities.